Role of glial cell derived neurotrophic factor in the protective effect of smilagenin on rat mesencephalic dopaminergic neurons damaged by MPP+

FEBS Letters

Volumn 582, Issue 6, 2008, Pages 956-960

  Zhang, Yongfang ^a   Xia, Zongqin ^a   Hu, Yaer ^a   Orsi, Antonia ^b   Rees, Daryl ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Phytopharm Co   (United Kingdom)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Dopaminergic neuron; GDNF receptor; Glial cell derived neurotrophic factor; Smilagenin; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA1; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA1 ANTIBODY; MESSENGER RNA; PROTEIN TYROSINE KINASE; RECEPTOR ANTIBODY; SAPOGENIN; SMILAGENIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; NERVE CELL CULTURE; NERVE FIBER GROWTH; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

RATTUS;

EID: 40149088924     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.02.039     Document Type: Article

References (23)

1. C.W. Olanow W.G. Tatton Etiology and pathogenesis of Parkinson’s disease Annu. Rev. Neurosci. 22 1999 123 144
2. J.M. Savitt V.L. Dawson T.M. Dowson Diagnosis and treatment of Parkinson disease: molecules to medicine J. Clin. Invest. 116 2006 1744 1754
3. M.A. Silverdale S.H. Fox A.R. Crossman J.M. Brotchie Potential nondopaminergic drugs for Parkinson’s disease Adv. Neurol. 91 2003 273 291
4. Q. Chen Y. He K. Yang Gene therapy for Parkinson’s disease: progress and challenges Curr. Gene Ther. 5 2005 71 80
5. M. Geraerts O. Krylyshkina Z. Debyser V. Baekelandt Concise review: therapeutic strategies for Parkinson Disease based on modulation of adult neurogenesis Stem Cells 25 2007 263 270
6. M.G. Murer Q. Yan R. Raisman-Vozari Brain-derived neurotrophic factor in the control human brain, and in Alzheimer’s disease and Parkinson’s disease Prog. Neurobiol. 63 2001 71 124
7. W.A. Cass L.E. Peters M.E. Harned K.B. Seroogy Protective by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine Ann. N.Y. Acad. Sci. 1074 2006 272 281
8. Y. Sagi S. Mandel T. Amit M.B. Youdim Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism Neurobiol. Dis. 25 2007 35 44
9. K. Radad G. Gille R. Moldzio H. Saito K. Ishige W.D. Rausch Ginsenoside Rb1 and Rg1 effects on survival and neurite outgrowth of MPP+-affected mesencephalic dopaminergic cells J. Neural. Transm. 111 2004 37 45
10. +-induced oxidative stress in mesencephalic neurons Eur. J. Pharmacol. 568 2007 142 148
11. T.P. Singer R.R. Ramsay Mechanism of neurotoxicity of MPTP. An Update FEBS Lett. 274 1990 1 8
12. S.E. Stephans G.W. Miller A.I. Levey J.T. Greenamyre Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells Neurotoxicology 23 2002 569 580
13. T.F. Oo N. Kholodilov R.E. Burke Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal glial cell line-derived neurotrophic factor in vivo J. Neurosci. 23 2003 5141 5148
14. P. Carmillo L. Dago E.S. Day D.S. Worley A. Rossomando L. Walus O. Orozco C. Buckley S. Miller A. Tse R.L. Cate C. Rosenblad D.W. Sah M. Gronborg A. Whitty Glial cell line-derived neurotrophic factor (GDNF) receptor α-1 (GFRα-1) is highly selective for GDNF versus artemin Biochemistry 44 2005 2545 2554
15. A. Brouard D. Pelaprat C. Dana M. Vial A.M. Lhiaubet W. Rostene Mesencephalic dopaminergic neurons in primary cultures express functional neurotensin receptors J. Neurosci. 12 1992 1409 1415
16. P. Chomczynski N. Sacchi Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction Anal. Biochem. 162 1987 156 159
17. M.C. Steel N.J. Buckley Differential regulation of muscarinic receptor mRNA levels in neuroblastoma cells by chronic agonist exposure: a comparative polymerase chain reaction study Mol. Pharmacol. 43 1993 694 701
18. S. Kaufman E.E. Kaufman Tyrosine hydroxylase R.L. Blakley S.J. Blenkovic Folates and Pterins Chemistry and Biochemistry of the Pterin Vol. 2 1985 John Wiley and Sons New York 251 352
19. W.L. Kuan C.B. Hurelbrink R.A. Barker Increased capacity for axonal outgrowth using xenogenic tissue in vitro and in a rodent model of Parkinson’s disease Xenotransplantation 13 2006 233 247
20. J. Lotharius L.L. Dugan K.L. O’Malley Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons J. Neurosci. 19 1999 1284 1293
21. H. Sauer C. Rosenblad A. Bjorklund Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion Proc. Natl. Acad. Sci. USA 92 1995 8935 8939
22. B. Jakobsen J.B. Gramsbergen A. Moller Dall C. Rosenblad J. Zimmer Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protective against MPP toxicity by GDNF Eur. J. Neurosci. 21 2005 2939 2948
23. M. Sun L.X. Kong X.D. Wang X.G. Liu Q.S. Gao A.I. Geller Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson’s disease Brain Res. 1052 2005 119 129